Capricor Therapeutics
Capricor Therapeutics develops cell and exosome-based therapeutics for muscular and other select diseases, with its lead product CAP-1002 in Phase 3 for Duchenne muscular dystrophy.
Company Overview
Capricor Therapeutics is engaged in the development of transformative cell and exosome-based therapeutics focused on the treatment and prevention of muscular and other selected diseases. Their innovative approach and commitment to groundbreaking science place them at the forefront of biotechnology.
Lead Product Candidate CAP-1002
CAP-1002 is Capricor Therapeutics' lead product candidate. It is an allogeneic cell therapy that is currently in Phase 3 clinical development, specifically aimed at treating Duchenne muscular dystrophy. This advanced treatment option seeks to provide new hope for patients suffering from this debilitating condition.
Exosome Technology Platform
Capricor Therapeutics is pioneering exosome technology as a next-generation therapeutic platform. This technology is designed for delivering nucleic acids and proteins to address a variety of diseases. The innovative approach holds the potential to revolutionize treatment methodologies across different medical conditions.
Strategic Partnership with Nippon Shinyaku
Capricor Therapeutics has entered into a strategic partnership with Nippon Shinyaku. This collaboration focuses on the exclusive commercialization and distribution of CAP-1002 in the United States and Japan, aiming to extend the reach and impact of their therapeutic solutions.
Participation in Project NextGen
As part of Project NextGen, an initiative by the U.S. Department of Health and Human Services, Capricor Therapeutics is working to advance a pipeline of new vaccines that provide broader protection against COVID-19. This involvement underscores their commitment to addressing urgent and evolving public health needs.
